The injections I administer are all prescribed in the UK as hydroxocobalamin
It inhibits NF-kB and reduces pro-inflammatory cytokine production
however, transient injection-site pain, mild headache, gastrointestinal upset, or fatigue can occur, and patients should be counselled to report persistent anorexia, constipation, or polyuria that may herald rising serum calcium
Immunogenicity: The FDA classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding (immunogenicity, impurities, and insufficient safety evidence for suggested administration routes)
Stacking these two peptides creates a powerful synergy